FundingWatcher
Home / Startups / By venture fund / OrbiMed portfolio companies

OrbiMed portfolio companies

Updated 16 Nov 2026

http://www.orbimed.com

OrbiMed portfolio companies
One-time CSV
  • 46 funded companies, 41 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-investor-orbimed-advisors.csv46 rows × 18 columns
CompanyCityLast roundAmountDate
Windward BioBaselSeries B$165.0M2026-05-04
Angitia BiopharmaceuticalsWestlake VillageSeries D$130.0M2026-02-05
Triveni BioWatertownSeries C$65.0M2026-06-17
Capstan TherapeuticsSan DiegoSeries B$175.0M2024-03-20
BlossomHill TherapeuticsSan DiegoSeries B$84.0M2025-12-10
Convergent TherapeuticsCambridgeSeries A$40.0M2024-09-24
Aspen NeuroscienceSan DiegoSeries C$115.0M2025-11-20
Sparrow PharmaceuticalsPortlandSeries B$95.0M2025-09-24

8 rows of the CSV in 5 of its 18 columns.

46
Startups
$7.8B
Total raised
8
Funded in the last 12 months
$917.0M
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

27 of 46
27 rows
Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
Triveni Bio Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. Biotech Watertown, United States Series C $65.0M 2026-06-17 $272.0M Polaris Partners, OrbiMed, Alexandria Venture Investments +2 11 to 50 2019
Windward Bio Windward Bio develops monoclonal antibodies for advanced immunological diseases. Biotech Basel, Switzerland Series B $165.0M 2026-05-04 $365.0M Qiming Venture Partners, OrbiMed, Novo Holdings +2 11 to 50 2024
Terremoto Biosciences Terremoto Biosciences develops medicines using lysine-based covalent chemistry. Biotech San Francisco, United States Series C $108.0M 2026-04-15 $358.0M OrbiMed, Novo Holdings, Third Rock Ventures +2 51 to 100 2021
Angitia Biopharmaceuticals Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases. Biotech Westlake Village, United States Series D $130.0M 2026-02-05 $406.0M Legend Capital, OrbiMed, Oriza Holdings +1 51 to 100 2018
Mirador Therapeutics Mirador Therapeutics develops precision medicines for immune-mediated diseases. Biotech San Diego, United States Series B $250.0M 2026-01-12 $730.0M OrbiMed, Fidelity, ARCH Venture Partners +1 11 to 50 2024
BlossomHill Therapeutics BlossomHill Therapeutics is a biopharmaceutical company focused on oncology and autoimmune disorders. Biotech San Diego, United States Series B $84.0M 2025-12-10 $257.0M OrbiMed, Cormorant Asset Management, Vivo Capital +2 11 to 50 2020
Aspen Neuroscience Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. Biotech San Diego, United States Series C $115.0M 2025-11-20 $387.0M Google Ventures, OrbiMed, EDBI +2 101 to 250 2018
Sparrow Pharmaceuticals Sparrow Pharmaceuticals develops treatments for type 2 diabetes and related metabolic conditions linked to elevated cortisol. Biotech Portland, United States Series B $95.0M 2025-09-24 $156.3M U.S. Venture Partners, OrbiMed, RiverVest 1 to 10 2013
ENYO Pharma ENYO Pharma is a biopharmaceutical company based in Lyon, France. Biotech Lyon, France Series C $7.0M 2025-06-12 $108.8M Bpifrance, OrbiMed, Sofinnova Partners +2 11 to 50 2014
Sirius Therapeutics Sirius Therapeutics is a biotechnology company developing RNAi therapies for cardiovascular diseases. Biotech San Diego, United States Series B $50.0M 2025-05-09 $110.0M OrbiMed, Hankang Capital, Creacion Ventures +1 11 to 50 2021
Verdiva Bio Verdiva Bio develops treatments for patients with obesity and cardiometabolic diseases. Biotech London, United Kingdom Series A $411.0M 2025-01-09 $411.0M General Atlantic, RA Capital Management, OrbiMed +1 11 to 50 2024
Alentis Therapeutics Alentis Therapeutics develops novel therapeutics for advanced liver disease and cancer. Biotech Allschwil, Switzerland Series D $181.4M 2024-11-12 Bpifrance, HTGF (High-Tech Gruenderfonds), RA Capital Management +2 51 to 100 2019
Convergent Therapeutics Convergent Therapeutics develops radiopharmaceutical therapies for prostate cancer. Health care Cambridge, United States Series A $40.0M 2024-09-24 $130.0M RA Capital Management, OrbiMed, Invus 1 to 10 2021
Pathalys Pharma Pathalys Pharma develops clinical therapeutics for late-stage chronic kidney disease. Biotech Raleigh, United States Series B $105.0M 2024-08-20 $266.0M KB Investment, OrbiMed, The Carlyle Group +2 1 to 10 2021
MBX Biosciences MBX Biosciences is a preclinical biotech company creating therapies for rare endocrine diseases. Biotech Carmel, United States Series C $63.5M 2024-08-05 $238.4M New Enterprise Associates, RA Capital Management, OrbiMed +2 11 to 50 2019
Asceneuron Asceneuron develops therapeutics for orphan tauopathies and Alzheimer's disease. Biotech Lausanne, Switzerland Series C $100.0M 2024-07-16 OrbiMed, Novo Holdings, EQT Life Sciences +1 1 to 10 2012
Capstan Therapeutics Capstan Therapeutics develops in vivo mRNA and gene-editing medicines for a broad range of diseases. Biotech San Diego, United States Series B $175.0M 2024-03-20 $340.0M RA Capital Management, OrbiMed, Alexandria Venture Investments +2 101 to 250 2021
Sionna Therapeutics Sionna Therapeutics develops small molecule therapies for treating cystic fibrosis. Biotech Natick, United States Series C $182.0M 2024-03-06 $292.0M RA Capital Management, OrbiMed, T. Rowe Price +2 11 to 50 2018
Koya Medical Koya Medical develops treatments for lymphedema and venous diseases. Biotech Oakland, United States Series C $30.0M 2023-11-15 $70.2M National Science Foundation, MedTech Innovator, OrbiMed +2 101 to 250 2018
Rampart Bioscience Rampart Bioscience develops gene medicines for long-lasting treatment of diverse diseases. Biotech La Jolla, United States Series A $85.0M 2023-10-24 $85.0M RA Capital Management, OrbiMed, Forbion Capital Partners +1 11 to 50 2019
Edge Medical Robotics Edge Medical Robotics designs, develops, and commercializes surgical robot platforms and medical devices. Hardware Shenzhen, China Series C $200.0M 2021-11-05 $308.0M Temasek, Mirae Asset Venture Investment, OrbiMed +1 11 to 50 2017
MobileODT MobileODT develops AI-based medical devices for cervical cancer screening. Artificial intelligence Tel Aviv, Israel Series C $4.0M 2020-08-12 MedTech Innovator, OrbiMed, VU Venture Partners +2 11 to 50 2012
Therachon Therachon is a global biotechnology company developing medicines for rare genetic diseases. Biotech Basel, Switzerland Series B $60.0M 2018-08-09 $100.0M Bpifrance, New Enterprise Associates, OrbiMed +2 1 to 10 2014
Nutrinia Nutrinia develops therapies for patients with intestinal failure. Biotech Ramat Gan, Israel Series D $30.0M 2016-08-18 OrbiMed, Pontifax, WuXi Healthcare Ventures +2 11 to 50 2003
OmniGuide OmniGuide develops and commercializes minimally invasive surgical tools as a medical device company. Hardware Lexington, United States Series F $15.0M 2013-09-26 $129.8M OrbiMed, 3i Group, Alliance Technology Ventures +2 251 to 500 2000
Treato Treato collects patient-written health experiences from blogs and forums to reveal patient opinions. Artificial intelligence Or Yehuda, Israel Series B $14.5M 2013-04-23 Western Technology Investment, OrbiMed, REV +1 11 to 50 2008
Rejuvenon Rejuvenon is a biopharmaceutical company developing and commercializing compounds for treating oncologic diseases. Biotech The Woodlands, United States Series B $37.0M 2004-06-23 $49.0M OrbiMed, Boston Millennia Partners, Prospect Venture Partners +1 1 to 10 2000

Table 1. OrbiMed portfolio companies: the 27 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 46.

Largest rounds

Last 12 months
# Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
1 Mirador Therapeutics Mirador Therapeutics develops precision medicines for immune-mediated diseases. Biotech San Diego, United States Series B $250.0M 2026-01-12 $730.0M OrbiMed, Fidelity, ARCH Venture Partners +1 11 to 50 2024
2 Windward Bio Windward Bio develops monoclonal antibodies for advanced immunological diseases. Biotech Basel, Switzerland Series B $165.0M 2026-05-04 $365.0M Qiming Venture Partners, OrbiMed, Novo Holdings +2 11 to 50 2024
3 Angitia Biopharmaceuticals Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases. Biotech Westlake Village, United States Series D $130.0M 2026-02-05 $406.0M Legend Capital, OrbiMed, Oriza Holdings +1 51 to 100 2018
4 Aspen Neuroscience Aspen Neuroscience is a biotechnology company that develops personalized cell therapies and autologous regenerative medicine. Biotech San Diego, United States Series C $115.0M 2025-11-20 $387.0M Google Ventures, OrbiMed, EDBI +2 101 to 250 2018
5 Terremoto Biosciences Terremoto Biosciences develops medicines using lysine-based covalent chemistry. Biotech San Francisco, United States Series C $108.0M 2026-04-15 $358.0M OrbiMed, Novo Holdings, Third Rock Ventures +2 51 to 100 2021
6 BlossomHill Therapeutics BlossomHill Therapeutics is a biopharmaceutical company focused on oncology and autoimmune disorders. Biotech San Diego, United States Series B $84.0M 2025-12-10 $257.0M OrbiMed, Cormorant Asset Management, Vivo Capital +2 11 to 50 2020
7 Triveni Bio Triveni Bio develops antibody-based therapeutics for immunological and inflammatory diseases. Biotech Watertown, United States Series C $65.0M 2026-06-17 $272.0M Polaris Partners, OrbiMed, Alexandria Venture Investments +2 11 to 50 2019

Table 2. OrbiMed portfolio companies: the 7 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 RA Capital Management Startup incubator Boston, United States 10 22%
2 Invus Private equity firm New York, United States 5 11% 1 Triveni Bio
3 Novo Holdings Corporate venture arm Hellerup, Denmark 4 9% 2 Windward Bio, Terremoto Biosciences
4 Alexandria Venture Investments Venture capital firm Pasadena, United States 4 9% 2 Triveni Bio, Aspen Neuroscience
5 Bpifrance Government investment office Maisons-alfort, France 4 9%
6 Blue Owl Private equity firm New York, United States 3 7% 2 Windward Bio, Mirador Therapeutics
7 Morningside Private equity firm Newton, United States 3 7% 1 Angitia Biopharmaceuticals
8 T. Rowe Price Private equity firm Baltimore, United States 3 7%
9 Fidelity Investment bank Boston, United States 3 7% 1 Mirador Therapeutics
10 Versant Ventures Venture capital firm Menlo Park, United States 3 7%
11 Qiming Venture Partners Venture capital firm Shanghai, China 2 4% 1 Windward Bio
12 Cormorant Asset Management Hedge fund Boston, United States 2 4% 2 Triveni Bio, BlossomHill Therapeutics
13 Wellington Management Private equity firm Boston, United States 2 4%
14 New Enterprise Associates Venture capital firm Menlo Park, United States 2 4%
15 Lightspeed Venture Partners Venture capital firm Menlo Park, United States 2 4%

Table 3. OrbiMed portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 44 96% $7.4B
Biotech 38 83% $6.8B
Software 11 24% $735.2M
Artificial intelligence 4 9% $169.3M
Hardware 2 4% $437.8M

Table 4. OrbiMed portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series A 9 20% $85.0M
Series B 15 33% $95.0M
Series C 14 30% $65.0M
Series D+ 8 17% $30.0M

Table 5. OrbiMed portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Countries

CountriesCompaniesShare
United States 30 65%
Switzerland 4 9%
Israel 4 9%
China 4 9%
France 2 4%
United Kingdom 1 2%
Germany 1 2%

Table 6. OrbiMed portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
San Diego 6 13%
Boston 3 7%
Basel 2 4%
Seattle 2 4%
Westlake Village 1 2%
Watertown 1 2%
Cambridge 1 2%
Portland 1 2%
London 1 2%
Carmel 1 2%
Be'er Sheva 1 2%
Allschwil 1 2%

Table 7. OrbiMed portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
June 2026 1 12% $65.0M
May 2026 1 12% $165.0M
April 2026 1 12% $108.0M
March 2026 1 12%
February 2026 1 12% $130.0M
January 2026 1 12% $250.0M
December 2025 1 12% $84.0M
November 2025 1 12% $115.0M

Table 8. OrbiMed portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 6 13% $718.0M
2025 7 15% $822.0M
2024 14 30% $1.5B
2023 5 11% $315.5M
2022 1 2% $63.0M
2021 2 4% $298.1M

Table 9. OrbiMed portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 3 7%
2020 to 2022 14 30%
2015 to 2019 13 28%
2010 to 2014 6 13%
Before 2010 10 22%

Table 10. OrbiMed portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 9 20%
11 to 50 21 46%
51 to 100 7 15%
101 to 250 7 15%
251 to 500 1 2%
501 to 1,000 1 2%

Table 11. OrbiMed portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many OrbiMed portfolio companies are on the list?
46, in the file dated 16 November 2026. 8 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 46 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

OrbiMed portfolio companies: 46 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Portfolio companies by country

Portfolio companies by city

Other venture fund portfolios

Cite: FundingWatcher, 46 startups, 16 November 2026. https://fundingwatcher.com/startups/investor/orbimed-advisors/